Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX517 in metastatic prostate cancer
NCT04662580Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of ARX517 in Metastatic Prostate Cancer (mPC) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Incidence of adverse events at 1.5 years. Started May 2021; status: active, not recruiting.
02
Drugs
ARX517
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT04662580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662580.